Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL Phase 3 Study of ION582 in Angelman syndrome
2024-519711-33-01Phase 3Authorised
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 3 trial of obudanersen in Angelman syndrome (AS), sponsored by Ionis Pharmaceuticals. Primary endpoint: Change in performance on the Expressive Communication subdomain raw score of the Bayley Scales for Infant and Toddler Development-4 without caregiver input in Cohort 1. Planned start Apr 2026; status: authorised.
02
Drugs
obudanersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on 2024-519711-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519711-33-01.